Pharmaceuticals: Commission refines intellectual property rules

Pharmaceuticals 2018 European Commission

The EPO – European Patent Office, has announced the 15 inventors short-listed for this prestigious prize – pioneers in a range of technical fields, from green plastics and oil-spill clean-up, to pharmaceuticals, medical imaging and satellite navigation. Gert-Jan Gruter (The Netherlands), nominated for the European Inventor Award 2017 in the category “Small and medium-sized enterprises – SMEs”. © European Patent Organisation , 2017 / Source: EC – Audiovisual Service / Photo: Heinz Troll

This article is brought to you in association with the European Commission.

The Commission is proposing a targeted adjustment to intellectual property rules to help Europe’s pharmaceutical companies tap into fast-growing global markets and foster jobs, growth and investments in the EU.

The EU has a strong intellectual property rights framework in place which protects Europe’s know-how and sustains the pharmaceutical industry’s world-class innovation capacity. To improve the current system further and remove a major competitive disadvantage of EU manufacturers, the Commission proposes a targeted amendment: the so-called ‘export manufacturing waiver’ to Supplementary Protection Certificates.

Supplementary Protection Certificates (SPCs) extend patent protection for medicinal products which must undergo lengthy testing and clinical trials prior to obtaining regulatory marketing approval. Thanks to the waiver, in the future EU-based companies will be entitled to manufacture a generic or biosimilar version of an SPC-protected medicine during the term of the certificate, if done exclusively for the purpose of exporting to a non-EU market where protection has expired or never existed. The waiver will support Europe’s pioneering role in pharmaceutical research and development.

Vice-President Jyrki Katainen, responsible for Jobs, Growth Investment and Competitiveness, said: “Europe is and should remain at the forefront of pharmaceutical research and manufacturing. Our rules on intellectual property protection of pharmaceuticals promote innovation and creativity. We are committed to the core rights and the length of this protection, which remain unchanged. Today we are proposing a well-calibrated adjustment to the current regime to remove a legal barrier that was preventing our companies from competing on equal terms on global markets where competition is fierce. We want to make sure that our pharmaceutical industry reaps the benefits of such competition.”

Elżbieta Bieńkowska, Commissioner for Internal Market, Industry, Entrepreneurship and SMEs, added: “Today’s proposal strikes a balance between the imperative to ensure the attractiveness of Europe for innovative pharmaceutical companies and the urgency to allow EU based generics and biosimilar to compete on the global markets. This will help create growth and high-skilled jobs in the EU. It could generate €1 billion net additional sales per year and up to 25 000 new jobs over 10 years. It will particularly benefit the many small and medium-sized enterprises in the field. In the medium term, more competition will improve patients’ access to a wider choice of medicines and alleviate public budgets.”

With the waiver, intellectual property (IP) protection for medicine production in Europe will remain the strongest in the world. SPC-protected medicines will retain their full market exclusivity in the EU.

The proposal is accompanied by a series of safeguards which will create transparency and prevent IP-infringing products from entering Member State markets. It goes hand in hand with other EU initiatives to defend Europe’s know-how and innovation leadership and protect patients against counterfeited medicines. It also complements the EU’s overall approach to ensure free and fair trade, characterised by open markets, for EU-based manufacturers.

Today’s proposal amends Regulation 469/2009 on the supplementary protection certificate for medicinal products. Once adopted by the European Parliament and Council, it will be directly applicable in all EU Member States.

Background

EU and global pharmaceutical markets are undergoing profound changes. Global demand for medicines has increased massively, reaching over €1 trillion in 2017. Alongside this, there is a shift towards an ever-greater market share for generics and biosimilars. Traditionally the EU has played a pioneering role in pharmaceutical research and development, including generic medicines and biosimilars. But this leadership position is under threat.

Supplementary protection certificates (SPCs) are an intellectual property right first introduced in the EU in 1992 as an extension to a patent right. Pharmaceutical SPCs aim to offset the loss of effective patent protection for medicines that occurs due to the compulsory lengthy testing and clinical trials these products require prior to obtaining regulatory marketing approval. An SPC can extend a patent right for a maximum of five years.

EU SPC rules are the strongest in the world. While they aim to reward investment in innovation and protect intellectual property, SPCs can put EU based manufacturers of generics and biosimilar at a disadvantage with non-EU based industry, thereby preventing further innovation and job creation in Europe. Indeed, during the SPC period of protection of the product in the EU, EU-based manufacturers of generic and/or biosimilar-related products cannot currently manufacture for any purpose, including export outside the EUto countries where SPC protection has expired or does not exist, while manufacturers based in those non-EU countries can do so. This major competitive disadvantage entails a risk of delocalisation of manufacturing and loss of investment in Europe. The certificate also makes it more difficult for EU manufacturers to enter the EU market immediately after its expiry, given that they are not in a position to build up production capacity until the protection provided by the certificate has lapsed.

Many SPC protections will start to lapse from 2020, as a significant number of medicinal products will enter the public domain, since their patent or SPC terms will expire. This development will generate significant new market opportunities for generics, and for biosimilars in particular. There is an urgent need to adjust the existing regulation to this situation, as the markets for generics and biosimilars are highly competitive and steadily growing and the investment decisions on the localisation of the production are being made well in advance.

Today’s proposal was announced in the Commission’s 2015 Single Market Strategy, and follows various studies, an extensive consultation and a European Parliament resolution endorsing the need to introduce before 2019 an SPC manufacturing waiver.

the sting Milestone

Featured Stings

Can we feed everyone without unleashing disaster? Read on

These campaigners want to give a quarter of the UK back to nature

How to build a more resilient and inclusive global system

Stopping antimicrobial resistance would cost just USD 2 per person a year

EU Presidents lay out priorities for future of Europe

Depression is the no. 1 cause of ill health and disability worldwide

When is Berlin telling the truth about the EU banking union?

UN chief calls for ‘increased commitment’ to resolution on 10th anniversary of Georgia conflict

Commission reinforces tools to ensure Europe’s interests in international trade

Data and the future of financial services

From social entrepreneurship to systems entrepreneurship: how to create lasting change

How migrants who send money home have become a global economic force

5 things to know about the exploding world of pro gaming

Coronavirus: Commission stands ready to continue supporting EU’s agri-food sector

EP Group leaders on Brexit: “the agreement is not open to renegotiation”

Ecuador: UN ‘stands ready’ to support talks, in bid to end political turmoil

COVID-19 threatens the developing world’s small businesses. This is how to save them

Amazon fires: Health Effects, Near and Far

Brazil must immediately end threats to independence and capacity of law enforcement to fight corruption

IMF: Sorry Greece it was a mistake of 11% of your GDP

EU Summit/Migration: Parliament calls for joint solutions based on solidarity

In Bahrain, Global Forum for Entrepreneurs and Investment examines empowerment of women, youth through innovation

How tomorrow’s buildings will make you – and the planet – healthier

The future of energy in Puerto Rico is renewable

One person dies by suicide every 40 seconds: new UN health agency report

Women outliving men ‘everywhere’, new UN health agency statistics report shows

EU budget: Commission helps prepare new Cohesion programmes with Regional Competitiveness Index and Eurobarometer

Is poverty and exclusion the necessary price for EU’s recovery?

How global tech can drive local healthcare innovation in China

MWC 2016 LIVE: Stripe gives payments leg-up to startups in emerging markets

The cost of housing is tearing our society apart

Release of prize-winning Reuters journalists in Myanmar welcomed by UN

Menu for change: why we have to go towards a Common Food Policy

This is what the UK’s major supermarkets say about plastic packaging and the environment

Environmental Implementation Review: Commission helps Member States to better apply EU environment rules to protect citizens and enhance their quality of life

The Junior Enterprise concept, one of the best ways to develop practical skills

The EU Parliament slams Commission on economic governance

Assault on key Yemeni port would endanger 300,000 children and ‘choke off’ aid for millions more: UNICEF chief

With science ‘held back by a gender gap’, Guterres calls for more empowerment for women and girls

Sign language protects ‘linguistic identity and cultural diversity’ of all users, says UN chief

Further reforms will move Slovakia toward a more innovative and inclusive society

Global economy: ‘we must do everything possible’ to avoid global ‘fracture’ caused by US-China tensions, urges Guterres

The mental domain in times of a pandemic

3 leadership lessons from the age of coronavirus

Ukraine undecided over a strategic partnership with the EU

“As long as we work together through thick and thin, more benefits can be delivered to the people of Eurasia”, China’s Premier Li Keqiang highlights from ASEM in Brussels

Electronic cigarettes, a better alternative or a well-advertised product

Ukraine jet crashes in Iran, killing 176: UN chief offers deepest condolences

The Linde Group Logo (Source: The Linde Group website, Press Services, 2018)

EU starts in-depth investigation of Linde-Praxair merger over competition concerns

This is how a smart factory actually works

Facebook/Cambridge Analytica: MEPs pursue personal data breaches probe

FROM THE FIELD: Keeping Morocco’s indigenous culture and conservation in balance

Uncovered liabilities of €5 billion may render EU insolvent

We must rethink and repurpose cybersecurity for the COVID-19 era

New General Assembly President brings ‘valuable insights’ into key UN challenges

The EU sides with China against the US; but has Germany capitulated to America?

Storms and snow in Lebanon worsen plight for Syrian refugees

Our tourism system is broken – time to customize

Deutsche Bank slammed by the US-based trio of IMF, Fed and Moody’s

Stronger European Border and Coast Guard to secure EU’s borders

DR Congo elections: ‘historic opportunity’ for ‘peaceful transfer of power’ says Security Council

It will take a lot more than free menstrual pads to end period poverty

Summertime Consultation: 84% want Europe to stop changing the clock

Why the foundations of the modern world are costing the earth

More Stings?

Advertising

Speak your Mind Here

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s